Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR OMNIPAQUE 300

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Omnipaque 300

Subscribe to access the full database, or Try it Free
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00478556 ↗	Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT	Completed	GE Healthcare	Phase 4	2007-08-01	Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT00478556 ↗	Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT	Completed	University of Alabama at Birmingham	Phase 4	2007-08-01	Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT00587132 ↗	Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma	Terminated	ChiRhoClin, Inc.	Phase 1/Phase 2	2006-11-01	The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
NCT00587132 ↗	Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma	Terminated	Mayo Clinic	Phase 1/Phase 2	2006-11-01	The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Omnipaque 300

Condition Name

Chart
Table

Condition Name for Omnipaque 300
Intervention	Trials
Lung Cancer Non-Small Cell Cancer (NSCLC)	1
Augmented Renal Clearance	1
Glomerular Filtration Rate	1
Lung Cancer Small Cell Lung Cancer (SCLC)	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Omnipaque 300
Intervention	Trials
Coronary Artery Disease	3
Myocardial Ischemia	2
Sepsis	1
Intestinal Obstruction	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Omnipaque 300

Trials by Country

Map
Table

Trials by Country for Omnipaque 300
Location	Trials
United States	47
France	2
Korea, Republic of	1
Colombia	1
Puerto Rico	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Omnipaque 300
Location	Trials
Pennsylvania	3
Minnesota	3
California	3
Ohio	2
Maryland	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Omnipaque 300

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Omnipaque 300
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
Phase 2	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Omnipaque 300
Clinical Trial Phase	Trials
Completed	8
Recruiting	7
Not yet recruiting	3
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Omnipaque 300

Sponsor Name

Chart
Table

Sponsor Name for Omnipaque 300
Sponsor	Trials
National Cancer Institute (NCI)	2
GE Healthcare	2
Duke Clinical Research Institute	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Omnipaque 300
Sponsor	Trials
Other	22
Industry	12
NIH	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon

Harvard Business School

Moodys

McKinsey

Baxter

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.